


IMMETCOLS

Immune-Metabolic prognostic signature



👉 Cancer Biomarker signature that classify patients in 3 clusters depending on their immuno-metabolic profile

? CLINICAL NEED / NEED

Immune check-point inhibitor (ICI) treatment efficacy ranges from **30-40% in sensitive tumors** to **<5% in immune-resistant tumors**.

Current Predictive methods have **low sensitivity and poor specificity** identifying patients that could benefit from ICI Treatment.

💡 SOLUTION

10-gene signature that **classifies patients** with solid tumors in **3 different clusters** depending on the immuno-metabolic profile.

🌟 COMPETITIVE ADVANTAGE

Identification ICI responder patients **better than the Standard of Care**.

Reduction of cost related to non-responder patients.


Early Identification of non-responder patients that could benefit from **other immuno-metabolic approaches**

🔒 INTELLECTUAL PROPERTY

International Patent Application
PCT/EP2022/073151 - August 2022
Applicants: HCB, IDIBAPS, CSIC, UB, ICREA

📊 DEVELOPMENT

Next steps will be the signature validation in a relevant environment and the Proof of Concept experiments by using organoids



🧩 LOOKING FOR...

Partners for **co-development** or **licensing**.



THE TEAM

Clínic Barcelona

IDIBAPS

CSIC
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS

ICREA

UNIVERSITAT DE BARCELONA



Dr. Joan Maurel
Principal Researcher



Dr. Marta Cascante
Principal Researcher



Dr. Timothy Thompson
Principal Researcher



CONTACT DETAILS

Knowledge and Technology
Transfer Office

innova@recerca.clinic.cat